Sector News

Sanofi poaches AstraZeneca scientist as new research head

March 29, 2016
Life sciences

French drugmaker Sanofi has poached one of AstraZeneca’s top scientists to be its new research head in another high-profile departure for the British drugmaker.

Sanofi said on Tuesday that Yong-Jun Liu had been appointed as head of research with effect from April 1, reporting to Elias Zerhouni, the group’s president of global research and development.

Liu, a specialist in immunology with more than 250 published articles in leading academic journals, currently heads up research at AstraZeneca’s MedImmune biotechnology division, a position he has held since 2014.

Prior to that he led programmes at Baylor Research Institute and the MD Anderson Cancer Center, where he was founding director of the Cancer Immunology Research Institute.

His decision to leave AstraZeneca follows the exit last June of Briggs Morrison, the company’s former chief medical officer and head of late-stage drug development, and respiratory and inflammatory medicines head James Ward-Lilley.

AstraZeneca is going through a transition as older drugs lose patent protection and it invests heavily in new medicines, especially in the field of cancer immunotherapy.

It has a promising pipeline of experimental drugs but has also suffered some recent setbacks, including last week’s failure of its marketed heart drug Brilinta as a treatment for stroke patients and earlier disappointing results with a drug to treat lung and abdominal cancer mesothelioma.

Sanofi, meanwhile, is seeking to rejuvenate its early-stage pipeline and Zerhouni said Liu’s experience in immunology, oncology and translational medicine would be “vital assets” for this task.

By Ben Hirschler

Source: Reuters

Related News

May 8, 2021

BD to spin off $1B diabetes care business into standalone public company

Life sciences

BD’s new company will have the freedom to expand its portfolio of tools and technologies for the chronic care of diabetes.

May 8, 2021

Galapagos cuts pipeline, targets €150M in savings after setbacks

Life sciences

The Belgian biotech is pulling out of metabolic diseases and osteoarthritis R&D to focus on its core therapeutic areas.

May 8, 2021

Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus

Life sciences

Catalent will use its new facility for commercial production of plasmid DNA, used to make a range of biologics, including viral vectors, mRNA and cell therapies.

Send this to a friend